Updates in Treatment Strategies for Hodgkin Lymphoma
Search for other papers by Ranjana H. Advani in
Current site
Google Scholar
PubMed
Several options are available for frontline treatment of advanced-stage Hodgkin lymphoma (HL) and treatment of relapsed HL, each with inherent advantages and disadvantages. Clinicians must balance risk with benefit for the individual patient. At the NCCN 2019 Annual Congress: Hematologic Malignancies, Dr. Ranjana H. Advani summarized the current frontline treatment options for advanced-stage HL and outlined novel and emerging agents that may be incorporated as therapy options for relapsed disease.
Disclosures: Dr. Advani has disclosed that she has received research support from Agensys, Inc., Celgene Corporation, Forty Seven, Inc., Janssen Pharmaceutica Products, LP, Kura Oncology, Inc., Merck & Co., Inc., Millennium Pharmaceuticals, Inc., Genentech, Inc./Roche Laboratories, Inc., Pharmacyclics, Regeneron Pharmaceuticals, Inc., Seattle Genetics, Inc.; and serves as a scientific advisor for AstraZeneca Pharmaceuticals LP, Bayer HealthCare, Gilead Sciences, Inc., Kite Pharma, Kyowa Hakko Kirin Co., Ltd., Cell Medica, Genentech, Inc./Roche Laboratories, Inc., Seattle Genetics, Inc., and Takeda Pharmaceuticals North America, Inc.
© 2019-2024 National Comprehensive Cancer Network